Skip To Main Content
Carl A. Valenstein on Muck Rack

Carl A. Valenstein

As seen in: Bloomberg Law, Law360, JD Supra, Lexology, Mondaq, Concurrences, Law360 UK, Massachusetts Lawyers Weekly
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Carl A.

Contact Carl A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

OFAC Launches Online Reconsideration Portal for Seeking Removal from Sanctions Lists

|
By Eli Rymland-Kelly, Katelyn Hilferty, Carl A. Valenstein
| morganlewis.com
The Office of Foreign Assets Control (OFAC) recently introduced its new Reconsideration Portal, a digital platform for requesting removal from the agency’s sanctions lists. The portal is designed to streamline the delisting process by guiding petitioners (and/or their counsel) to submit all necessary information at the onset, reducing the follow-up requests that have historically delayed OFAC’s adjudication and encouraging more complete submissions from the start.
Open in Who Shared Issue with article?

DOJ’s Bulk Sensitive Personal Data Rule: A Cross-Border Compliance Imperative for the Life Sciences Industry

|
By Todd Liao, David Plotinsky, Carl A. Valenstein
| morganlewis.com
For the life sciences industry, the flow of human genomic data, biospecimens, and clinical trial records across borders is not merely an operational detail, it is the lifeblood of global research and development. But the regulatory environment governing the flow of this data and materials has shifted dramatically. Now at the end of its initial grace period, the US Department of Justice’s Data Security Program is in full effect.
Open in Who Shared Issue with article?

US-China biotech transactions: Navigating each country’s evolving regulatory landscape

|
By Todd Liao, Morgan Lewis, Carl A. Valenstein
| globalrelay.com
Photo: Cheng Xin/Getty Images The regulatory landscape governing US-China biotech transactions is evolving rapidly on both sides of the Pacific. Multiple legislative proposals, executive actions, and administrative rulemakings are proceeding in parallel, each at different stages of maturity and each subject to significant political uncertainty.
Open in Who Shared Issue with article?
See all 167 articles